A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PART I We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients. After nearly eight years of platform development and treatment of more than 200 patients across six clinical studies, multiple anticipated clinical readouts are expected in the second quarter of 2026.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | - | - |
| Net Income | -191M | -191M | -258M | -1.6B | -1.2B | -903M |
| EPS | $-0.87 | $-0.87 | $-1.32 | $-2.09 | $-2.38 | $-1.34 |
| Free Cash Flow | -150M | -150M | -201M | -239M | -226M | -206M |
| ROIC | -68.7% | -53.4% | -61.0% | -50.5% | -39.7% | -38.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.42 | 0.30 | 0.25 | 0.23 | 0.14 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -209M | -209M | -273M | -328M | -336M | -180M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -65.3% | -53.4% | -61.0% | -305.0% | -185.3% | -97.6% |
| Shares Outstanding | 219M | 219M | 195M | 217M | 169M | 144M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0 | N/A | N/A | N/A | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 193M | 220M | 256M | 243M | 192M | 150M | 150M |
| SG&A | 65M | 74M | 79M | 72M | 65M | 57M | 57M |
| EBIT | -258M | -180M | -336M | -328M | -273M | -209M | -209M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -250M | -903M | -1.2B | -1.6B | -258M | -191M | -191M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 13M | 16M | 7.1M | 7.1M |
| Returns on Capital | |||||||
| ROIC | -23.2% | -38.5% | -39.7% | -50.5% | -61.0% | -53.4% | -68.7% |
| ROE | -23.2% | -97.6% | -185.3% | -305.0% | -61.0% | -53.4% | -65.3% |
| ROA | -20.4% | -86.0% | -150.4% | -243.0% | -46.9% | -39.6% | -45.9% |
| Cash Flow | |||||||
| Op. Cash Flow | -115M | -185M | -221M | -238M | -200M | -149M | -149M |
| Free Cash Flow | -181M | -206M | -226M | -239M | -201M | -150M | -150M |
| Owner Earnings | -188M | -276M | -318M | -318M | -266M | -199M | -199M |
| CapEx | 66M | 21M | 5.2M | 1.5M | 694K | 386K | 386K |
| Maint. CapEx | 7.6M | 10M | 14M | 14M | 14M | 12M | 12M |
| Growth CapEx | 58M | 11M | 0 | 0 | 0 | 0 | 0 |
| D&A | 7.6M | 10M | 14M | 14M | 14M | 12M | 12M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 65M | 81M | 84M | 66M | 52M | 38M | 38M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -777M | N/A | N/A | N/A | N/A | N/A | -52M |
| Cash & Equiv. | 183M | 173M | 62M | 83M | 75M | 52M | 52M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.05 | 0.14 | 0.23 | 0.25 | 0.30 | 0.42 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | -1509.4 | -194.7 | -194.7 |
| Equity | 1.1B | 925M | 667M | 512M | 422M | 293M | 293M |
| Total Assets | 1.2B | 1.1B | 822M | 643M | 549M | 416M | 416M |
| Total Liabilities | 148M | 126M | 155M | 131M | 127M | 123M | 123M |
| Intangibles | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -646M | -895M | -1.2B | -1.6B | -1.8B | -2.0B | -2.0B |
| Working Capital | 751M | 423M | 475M | 422M | 268M | 225M | 225M |
| Current Assets | 845M | 471M | 529M | 459M | 303M | 258M | 258M |
| Current Liabilities | 94M | 48M | 54M | 37M | 36M | 33M | 33M |
| Per Share Data | |||||||
| EPS | -2.08 | -1.34 | -2.38 | -2.09 | -1.32 | -0.87 | -0.87 |
| Owner EPS | -1.56 | -1.91 | -1.88 | -1.46 | -1.36 | -0.91 | -0.91 |
| Book Value | 8.97 | 6.40 | 3.94 | 2.36 | 2.16 | 1.33 | 1.33 |
| Cash Flow/Share | -0.96 | -1.28 | -1.30 | -1.09 | -1.03 | -0.68 | -0.81 |
| Dividends/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 120.3M | 144.5M | 169.1M | 217.3M | 195.1M | 219.4M | 219.4M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -2.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.0 | 2.3 | 1.2 | 1.0 | 1.0 | N/A | 1.7 |
| Price/Sales | N/A | 30.9 | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -5.6% | -9.9% | -27.3% | -46.7% | -47.0% | N/A | -29.9% |
| Market Cap | 3.3B | 2.1B | 827M | 512M | 427M | 0 | 500M |
| Avg. Price | 32.65 | 25.94 | 10.66 | 4.77 | 3.06 | 0.00 | 2.28 |
| Year-End Price | 27.02 | 15.41 | 5.78 | 3.27 | 2.19 | 0.00 | 2.28 |
Allogene Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Allogene Therapeutics, Inc. (ALLO) has a 5-year average return on invested capital (ROIC) of -48.6%. This is below average and may indicate limited pricing power.
Allogene Therapeutics, Inc. (ALLO) has a market capitalization of $500M. It is classified as a small-cap stock.
Allogene Therapeutics, Inc. (ALLO) does not currently pay a regular dividend.
Allogene Therapeutics, Inc. (ALLO) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Allogene Therapeutics, Inc. (ALLO) generated $-150 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Allogene Therapeutics, Inc. (ALLO) has a debt-to-equity ratio of 0.42. This indicates a conservatively financed balance sheet.
Allogene Therapeutics, Inc. (ALLO) reported earnings per share (EPS) of $-0.87 in its most recent fiscal year.
Allogene Therapeutics, Inc. (ALLO) has a return on equity (ROE) of -53.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for Allogene Therapeutics, Inc. (ALLO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Allogene Therapeutics, Inc. (ALLO) has a book value per share of $1.33, based on its most recent annual SEC filing.